Cargando…

“Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy

Transthyretin familial amyloid polyneuropathy (TTR‐FAP) is a rare, progressive, life‐threatening, hereditary disorder caused by mutations in the transthyretin gene and characterized by extracellular deposition of transthyretin‐derived amyloid fibrils in peripheral and autonomic nerves, heart, and ot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Conceição, Isabel, González‐Duarte, Alejandra, Obici, Laura, Schmidt, Hartmut H.‐J., Simoneau, Damien, Ong, Moh‐Lim, Amass, Leslie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788142/ https://www.ncbi.nlm.nih.gov/pubmed/26663427 http://dx.doi.org/10.1111/jns.12153

Ejemplares similares

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H.‐J., et al.
Publicado: (2016)

Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy
por: González‐Duarte, Alejandra, et al.
Publicado: (2020)

Estimating the global prevalence of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H., et al.
Publicado: (2018)

Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm
por: Sekijima, Yoshiki, et al.
Publicado: (2018)

Correction to: Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm
por: Sekijima, Yoshiki, et al.
Publicado: (2019)

Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy
por: Warendorf, Janna K., et al.
Publicado: (2023)

Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal
por: Inês, Mónica, et al.
Publicado: (2015)

Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
por: Waddington-Cruz, Márcia, et al.
Publicado: (2019)

Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Waddington‐Cruz, Márcia, et al.
Publicado: (2021)

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2013)

Diagnosis of wild‐type transthyretin amyloid cardiomyopathy in Japan: red‐flag symptom clusters and diagnostic algorithm
por: Inomata, Takayuki, et al.
Publicado: (2021)

Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial
por: Keohane, Denis, et al.
Publicado: (2015)

Transthyretin familial amyloid polyneuropathy impact on health-related quality of life
por: Inês, Mónica, et al.
Publicado: (2015)

Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
por: Amass, Leslie, et al.
Publicado: (2018)

Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy
por: Stewart, Michelle, et al.
Publicado: (2015)

Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy
por: Waddington-Cruz, Marcia, et al.
Publicado: (2015)

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
por: Falcão de Campos, Catarina, et al.
Publicado: (2023)

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
por: Waddington Cruz, Márcia, et al.
Publicado: (2016)

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
por: Adams, David, et al.
Publicado: (2016)

Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers
por: Salvalaggio, Alessandro, et al.
Publicado: (2020)

The rehabilitation in the management of Transthyretin Familial Amyloid Polyneuropathy
por: Morier, Agnès, et al.
Publicado: (2015)

Psychopathological Dimensions in Portuguese Subjects with Transthyretin Familial Amyloid Polyneuropathy
por: Lopes, Alice, et al.
Publicado: (2017)

Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Mundayat, Rajiv, et al.
Publicado: (2018)

Ocular manifestations of transthyretin-related familial amyloid polyneuropathy
por: Rousseau, Antoine, et al.
Publicado: (2015)

Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy
por: Romero-Imbroda, Jesús, et al.
Publicado: (2017)

Post Hoc Analysis of Nutritional Status in Patients with Transthyretin Familial Amyloid Polyneuropathy: Impact of Tafamidis
por: Suhr, Ole B., et al.
Publicado: (2014)

Vasculopathy in transthyretin Val30Met familial amyloid polyneuropathy
por: Koike, Haruki, et al.
Publicado: (2015)

Ophtalmologic changes in transthyretin familial amyloid polyneuropathy (ATTR-FAP)
por: Ferreira, Natália
Publicado: (2015)

Nerve Ultrasound Comparison Between Transthyretin Familial Amyloid Polyneuropathy and Chronic Inflammatory Demyelinating Polyneuropathy
por: Du, Kang, et al.
Publicado: (2021)

Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer
por: Cotrina, Ellen Y., et al.
Publicado: (2020)

Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France
por: Mariani, Louise‐Laure, et al.
Publicado: (2015)

Transthyretin familial amyloid polyneuropathy (TTR‐FAP): Parameters for early diagnosis
por: Escolano‐Lozano, Fabiola, et al.
Publicado: (2017)

Clinical and genetic features of transthyretin-related familial amyloid polyneuropathy in China
por: Liu, Lei, et al.
Publicado: (2020)

Patterns of myelinated nerve fibers loss in transthyretin amyloid polyneuropathy and mimics
por: Du, Kang, et al.
Publicado: (2022)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Clinical, epidemiological, genetic, and electrophysiological characteristics of transthyretin familial amyloid polyneuropathies in Israel
por: Sadeh, Menachem, et al.
Publicado: (2015)

Inflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin
por: Suenaga, Genki, et al.
Publicado: (2017)

Prevalence of hereditary transthyretin amyloid polyneuropathy in idiopathic progressive neuropathy in conurban areas
por: Thimm, Andreas, et al.
Publicado: (2019)

Transthyretin interacts with actin regulators in a Drosophila model of familial amyloid polyneuropathy
por: I. Oliveira da Silva, Marina, et al.
Publicado: (2020)

Vagus nerve ultrasound in transthyretin familial amyloid polyneuropathy: A pilot study
por: Du, Kang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b418f8jn99a75sgsq8m7d35on0